(S)-2-amino-3-(4'-cyano-biphenyl-4-yl)-propionic acid methyl ester | 1187090-65-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-2-amino-3-(4'-cyano-biphenyl-4-yl)-propionic acid methyl ester
• 英文别名: Methyl (s)-2-amino-3-(4'-cyano-[1,1'-biphenyl]-4-yl)propanoate；methyl (2S)-2-amino-3-[4-(4-cyanophenyl)phenyl]propanoate
• CAS: 1187090-65-8
• 化学式: C₁₇H₁₆N₂O₂
• 分子量: 280.326
• InChiKey: SEXYDEKFJLXIME-INIZCTEOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  76.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (3S,8S)-3-[4-(3,4-Dichloro-benzyloxy)-phenyl]-7-((R)-1-phenyl-propyl)-2,3,6,7,8,9-hexahydro-[1,4]dioxino[2,3-g]isoquinoline-8-carboxylic acid 、 (S)-2-amino-3-(4'-cyano-biphenyl-4-yl)-propionic acid methyl ester 以to give (S)-3-(4′-cyano-biphenyl-4-yl)-2-{[(3S,8S)-3-[4-(3,4-dichloro-benzyloxy)-phenyl]-7-((R)-1-phenyl-propyl)-2,3,6,7,8,9-hexahydro-[1,4]dioxino[2,3-g]isoquinoline-8-carbonyl]-amino}-propionic acid methyl ester (30 mg)的产率得到(S)-3-(4'-cyano-biphenyl-4-yl)-2-{[(3S,8S)-3-[4-(3,4-dichloro-benzyloxy)-phenyl]-7-((R)-1-phenyl-propyl)-2,3,6,7,8,9-hexahydro-[1,4]dioxino[2,3-g]isoquinoline-8-carbonyl]-amino}-propionic acid methyl ester
  参考文献：
  名称：

  Substituted Azoanthracene Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof

  摘要：

  本发明涉及取代的偶氮蒽衍生物或其药学上可接受的盐，其调节人类GLP-1受体并可用于治疗调节人类GLP-1受体有益的疾病、疾病或病状，例如2型糖尿病。本发明还涉及包含这些化合物的制药组合物以及将这些化合物和组合物用于治疗这些有益的疾病、疾病或病状的用途。

  公开号：

  US20130096150A1

文献信息

• Oxadiazoanthracene compounds for the treatment of diabetes
  申请人：TransTech Pharma, LLC

  公开号：US09120813B2

  公开（公告）日：2015-09-01

  The present invention provides methods of use of oxadiazoanthracene derivatives of the formula (I) and pharmaceutically acceptable salts thereof, wherein A, B, C, R, R1, R2, R3, R4 and R5 are as herein described, and wherein said methods of use include uses for the treatment of disorders and diseases, such as diabetes.

  本发明提供了一种使用氧二氮杂蒽衍生物（I）及其药用可接受盐的方法，其中A、B、C、R、R1、R2、R3、R4和R5如本文所述，并且所述使用方法包括用于治疗疾病和疾病，如糖尿病。
• Oxadiazoanthracene Compounds For The Treatment Of Diabetes
  申请人：Mjalli Adnan M.M.

  公开号：US20090306063A1

  公开（公告）日：2009-12-10

  The present invention provides oxadiazoanthracene derivatives of the formula (I), wherein A, B, C, R, R 1 , R 2 , R 3 , R 4 and R 5 are as herein described, pharmaceutical compositions comprising oxadiazoanthracene derivatives, use of the oxadiazoanthracene derivatives for the preparation of pharmaceutical compositions, methods of use thereof for the treatment and/or prevention of disorders and diseases, such as diabetes, and intermediates useful for the preparation of oxadiazoanthracene derivatives of Formula (I).

  本发明提供了式(I)的氧杂二氮蒽衍生物，其中A、B、C、R、R1、R2、R3、R4和R5如本文所述，以及含有氧杂二氮蒽衍生物的制药组合物，使用氧杂二氮蒽衍生物制备制药组合物的用途，以及用于治疗和/或预防疾病和疾病（如糖尿病）的方法，以及用于制备式(I)的氧杂二氮蒽衍生物的中间体。
• OXADIAZOANTHRACENE COMPOUNDS FOR THE TREATMENT OF DIABETES
  申请人：Mjalli Adnan M.M.

  公开号：US20100197677A1

  公开（公告）日：2010-08-05

  The present invention provides methods of use of oxadiazoanthracene derivatives of the formula (I) and pharmaceutically acceptable salts thereof, wherein A, B, C, R, R 1 , R 2 , R 3 , R 4 and R 5 are as herein described, and wherein said methods of use include uses for the treatment and/or prevention of disorders and diseases, such as diabetes.

  本发明提供了氧二唑蒽衍生物及其药学上可接受的盐的使用方法，其化学式为(I)，其中A、B、C、R、R1、R2、R3、R4和R5如本文所述，其中所述的使用方法包括用于治疗和/或预防疾病和疾病，例如糖尿病。
• SUBSTITUTED AZOANTHRACENE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF
  申请人：Mjalli Adnan M.M.

  公开号：US20110160198A1

  公开（公告）日：2011-06-30

  The present invention is directed to substituted azoanthracene derivatives or pharmaceutically acceptable salts thereof that modulate the human GLP-1 receptor and that may be useful in the treatment of diseases, disorders, or conditions in which modulation of the human GLP-1 receptor is beneficial, such as diabetes mellitus type 2. The invention is also directed to pharmaceutical compositions comprising these compounds and to the use of these compounds and compositions in the treatment of such diseases, disorders, or conditions in which modulation of the human GLP-1 receptor is beneficial.

  本发明涉及替代的偶氮蒽衍生物或其药学上可接受的盐，其调节人类GLP-1受体，并可用于治疗调节人类GLP-1受体有益的疾病、紊乱或病症，如2型糖尿病。本发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在治疗调节人类GLP-1受体有益的这些疾病、紊乱或病症中的使用。
• Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof
  申请人：Mjalli Adnan M. M.

  公开号：US08383644B2

  公开（公告）日：2013-02-26

  The present invention is directed to substituted azoanthracene derivatives or pharmaceutically acceptable salts thereof that modulate the human GLP-1 receptor and that may be useful in the treatment of diseases, disorders, or conditions in which modulation of the human GLP-1 receptor is beneficial, such as diabetes mellitus type 2. The invention is also directed to pharmaceutical compositions comprising these compounds and to the use of these compounds and compositions in the treatment of such diseases, disorders, or conditions in which modulation of the human GLP-1 receptor is beneficial.

  本发明涉及取代的偶氮蒽衍生物或其药学上可接受的盐，其调节人类GLP-1受体，并可在治疗调节人类GLP-1受体有益的疾病、疾病、或病情，如2型糖尿病。本发明还涉及包含这些化合物的制药组合物，以及在治疗这些有益的疾病、疾病或病情中使用这些化合物和组合物。